Ultragenyx药业

RARE NASDAQ
59.52
-0.72
-1.20%
盘后: 59.52 0 0.00% 18:07 06/25 EDT
开盘
60.68
昨收
60.24
最高
61.48
最低
59.21
成交量
29.06万
成交均量(3M)
46.20万
52周最高
90.98
52周最低
37.44
换手率
0.51%
市值
34.21亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Ultragenyx药业 RARE股票价格,Ultragenyx药业股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
展开 >

最近浏览

名称
价格
涨跌幅